Warning! GuruFocus detected
4 Severe warning signs
with BPC.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Birzeit Pharmaceutical Co
ISIN : PS2015112738
Compare
Compare
Traded in other countries / regions
BPC.Palestine IPO Date
2004-12-22Description
Birzeit Pharmaceutical Co is engaged in manufacturing pharmaceutical products. It produces Ampoules, Capsules, Tablets and Caplets, Syrups, Suspensions and Granules, Ophthalmic, Semi-solids, Powder vials, Suppositories, and Powders. It serves the Ministry of Health, local healthcare organizations, international healthcare organizations and programs, and end users through pharmacies and physicians. It carries out its activity in Palestine, Algeria, and East Europe.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.81 | |||||
Interest Coverage | 144.34 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.78 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.2 | |||||
3-Year EBITDA Growth Rate | -19.8 | |||||
3-Year EPS without NRI Growth Rate | -12.9 | |||||
3-Year FCF Growth Rate | 28.1 | |||||
3-Year Book Growth Rate | 4.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 86.52 | |||||
9-Day RSI | 61.23 | |||||
14-Day RSI | 49.61 | |||||
3-1 Month Momentum % | -7.5 | |||||
6-1 Month Momentum % | -2.63 | |||||
12-1 Month Momentum % | -8.42 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.45 | |||||
Quick Ratio | 4.53 | |||||
Cash Ratio | 1.21 | |||||
Days Inventory | 1486.27 | |||||
Days Sales Outstanding | 346.69 | |||||
Days Payable | 107.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.36 | |||||
Dividend Payout Ratio | 0.41 | |||||
3-Year Dividend Growth Rate | -21.9 | |||||
Forward Dividend Yield % | 1.36 | |||||
5-Year Yield-on-Cost % | 1.36 | |||||
Shareholder Yield % | 1.36 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 32.45 | |||||
Operating Margin % | 18.82 | |||||
Net Margin % | 12.75 | |||||
FCF Margin % | 17.12 | |||||
ROE % | 5.08 | |||||
ROA % | 4.17 | |||||
ROIC % | 6.36 | |||||
3-Year ROIIC % | -46.84 | |||||
ROC (Joel Greenblatt) % | 8.36 | |||||
ROCE % | 5.32 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 28.17 | |||||
PE Ratio without NRI | 30.25 | |||||
Shiller PE Ratio | 13.24 | |||||
Price-to-Owner-Earnings | 40.55 | |||||
PS Ratio | 3.51 | |||||
PB Ratio | 1.37 | |||||
Price-to-Tangible-Book | 1.37 | |||||
Price-to-Free-Cash-Flow | 20.5 | |||||
Price-to-Operating-Cash-Flow | 20.5 | |||||
EV-to-EBIT | 20.73 | |||||
EV-to-EBITDA | 18.49 | |||||
EV-to-Revenue | 3.11 | |||||
EV-to-FCF | 18.18 | |||||
Price-to-GF-Value | 0.98 | |||||
Price-to-Projected-FCF | 0.98 | |||||
Price-to-Median-PS-Value | 1.19 | |||||
Price-to-Graham-Number | 1.36 | |||||
Price-to-Net-Current-Asset-Value | 3.15 | |||||
Earnings Yield (Greenblatt) % | 4.82 | |||||
FCF Yield % | 4.87 | |||||
Forward Rate of Return (Yacktman) % | -10.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Birzeit Pharmaceutical Co Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 40.651 | ||
EPS (TTM) ($) | 0.131 | ||
Beta | - | ||
3-Year Sharpe Ratio | 0.09 | ||
3-Year Sortino Ratio | 0.14 | ||
Volatility % | 26.41 | ||
14-Day RSI | 49.61 | ||
14-Day ATR ($) | 0.018551 | ||
20-Day SMA ($) | 3.656 | ||
12-1 Month Momentum % | -8.42 | ||
52-Week Range ($) | 3.55 - 4.35 | ||
Shares Outstanding (Mil) | 38.76 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Birzeit Pharmaceutical Co Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Birzeit Pharmaceutical Co Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Birzeit Pharmaceutical Co Frequently Asked Questions
What is Birzeit Pharmaceutical Co(XPAE:BPC)'s stock price today?
The current price of XPAE:BPC is $3.69. The 52 week high of XPAE:BPC is $4.35 and 52 week low is $3.55.
When is next earnings date of Birzeit Pharmaceutical Co(XPAE:BPC)?
The next earnings date of Birzeit Pharmaceutical Co(XPAE:BPC) is .
Does Birzeit Pharmaceutical Co(XPAE:BPC) pay dividends? If so, how much?
The Dividend Yield %  of Birzeit Pharmaceutical Co(XPAE:BPC) is 1.36% (As of Today), Highest Dividend Payout Ratio of Birzeit Pharmaceutical Co(XPAE:BPC) was 0.92. The lowest was 0.29. And the median was 0.56. The  Forward Dividend Yield % of Birzeit Pharmaceutical Co(XPAE:BPC) is 1.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |